user

The role of combined fludarabine, cyclophosphamide and rituximab chemoimmunotherapy in chronic lymphocytic leukemia: current evidence and controversies

被引：19
|
作者：
Skarbnik, Alan P. [1 ]
Faderl, Stefan [2 ]
机构：
[1] Hackensack Univ, Med Ctr, Div Lymphoma, John Theurer Canc Ctr,Blood & Marrow Transplantat, 92 Second St, Hackensack, NJ 07624 USA
[2] Hackensack Univ, Med Ctr, Div Leukemia, John Theurer Canc Ctr, Hackensack, NJ USA
来源：
THERAPEUTIC ADVANCES IN HEMATOLOGY | 2017年 / 8卷 / 03期
关键词：
chemoimmunotherapy; CLL; FCR; fludarabine; rituximab; PREVIOUSLY UNTREATED PATIENTS; LOW-DOSE FLUDARABINE; INITIAL THERAPY; OPEN-LABEL; AGENT; CHLORAMBUCIL; REGIMEN; FCR; CHEMOTHERAPY; VINCRISTINE;
D O I：
10.1177/2040620716681749
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Chemoimmunotherapy (CIT) has become a cornerstone in the treatment of patients with chronic lymphocytic leukemia (CLL). The combination of fludarabine, cyclophosphamide and rituximab (FCR) has emerged as the standard of care for therapy of previously untreated patients with CLL who are younger than 65 years and have no significant comorbidities. In this article, we review the role of FCR in the current treatment paradigm for CLL.
引用
收藏
页数：8
相关论文
共 50 条
  • [21] Combined fludarabine and rituximab for low grade lymphoma and chronic lymphocytic leukemia
    Savage, DG
    Cohen, NS
    Hesdorffer, CS
    Heitjan, D
    Oster, MW
    Garrett, TJ
    Bar, M
    Del Prete, S
    March, R
    Lonberg, M
    Talbot, S
    Mears, JG
    Flamm, M
    Taub, RN
    Nichols, G
    LEUKEMIA & LYMPHOMA, 2003, 44 (03) : 477 - 481
  • [22] Refining prognosis after first-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy in chronic lymphocytic leukaemia
    Smolej, Lukas
    LANCET ONCOLOGY, 2019, 20 (11): : 1478 - 1479
  • [23] Rituximab, fludarabine, and cyclophosphamide versus fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia: A systematic review with meta-analysis
    Nunes, Altacilio Aparecido
    da Silva, Anderson Soares
    Souza, Kathiaja Miranda
    Silva Koury, Christine de Nazare
    de Mello, Luane Marques
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2015, 94 (03) : 261 - 269
  • [24] Economic evaluation of rituximab added to fludarabine plus cyclophosphamide versus fludarabine plus cyclophosphamide for the treatment of chronic lymphocytic leukemia
    Felipe Casado, Luis
    Garcia Marco, Jose Antonio
    Gilsanz, Florinda
    Gonzalez, Marcos
    Rios, Eduardo
    de la Serna, Javier
    Urbano, Alvaro
    Vicente, Vicente
    Rubio-Terres, Carlos
    Castro, Antonio J.
    GACETA SANITARIA, 2011, 25 (04) : 274 - 281
  • [25] COST-EFFECTIVENESS OF RITUXIMAB COMBINED WITH FLUDARABINE AND CYCLOPHOSPHAMIDE IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN FRANCE
    Roussel, M.
    Troussard, X.
    Delmer, A.
    Poinso, M.
    Miadi-Fargier, H.
    VALUE IN HEALTH, 2009, 12 (07) : A270 - A270
  • [26] Chemoimmunotherapy with Cyclophosphomide, Fludarabine, Alemtuzumab and Rituximab (CFAR) Is Effective in Relapsed Patients with Chronic Lymphocytic Leukemia
    Badoux, Xavier C.
    Keating, Michael
    O'Brien, Susan
    Kadia, Tapan
    Ferrajoli, Alessandra
    Faderl, Stefan
    Koller, Charles
    Garcia-Manero, Guillermo
    Burger, Jan A.
    Wierda, William G.
    BLOOD, 2009, 114 (22) : 1332 - 1333
  • [27] Chemoimmunotherapy May Not Be Dead Yet in Chronic Lymphocytic Leukemia, But Fludarabine Plus Cyclophosphamide Plus Rituximab Is Potentially Facing Life Support Reply
    Brown, Jennifer R.
    Kay, Neil E.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (36) : 4094 - +
  • [28] Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia
    Short, Nicholas J.
    Keating, Michael J.
    Wierda, William G.
    Faderl, Stefan
    Ferrajoli, Alessandra
    Estrov, Zeev
    Smith, Susan C.
    O'Brien, Susan M.
    CANCER, 2015, 121 (21) : 3869 - 3876
  • [29] The Fate of Chronic Lymphocytic Leukemia Patients After Failure of Fludarabine, Cyclophosphamide, and Rituximab Regimen
    Panovska, Anna
    Lysak, Daniel
    Smolej, Lukas
    Brychtova, Yvona
    Simkovic, Martin
    Motyckova, Monika
    Lindtnerova, Michaela
    Trbusek, Martin
    Malcikova, Jitka
    Pospisilova, Sarka
    Mayer, Jiri
    Doubek, Michael
    BLOOD, 2012, 120 (21)
  • [30] The outcome of chronic lymphocytic leukemia patients who relapsed after fludarabine, cyclophosphamide, and rituximab
    Panovska, Anna
    Smolej, Lukas
    Lysak, Daniel
    Brychtova, Yvona
    Simkovic, Martin
    Motyckova, Monika
    Vodarek, Pavel
    Lindtnerova, Michaela
    Trbusek, Martin
    Malcikova, Jitka
    Pospisilova, Sarka
    Mayer, Jiri
    Doubek, Michael
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2013, 90 (06) : 479 - 485
12345